CUDC-101 - HDAC/EGFR/HER2 Inhibitor. CAS# 1012054-59-9 60129 Smiles: COC(=O)CCC1C2=CC3=NC(=CC4NC(C=C5N=C(C=C(N2)C=1C)[C@]1(C)[C@@H](C(=CC=C15)C(=O)OC)C(=O)OC)=C(C)C=4C=C)C(C)=C3CCC(O)=O

Smiles: COC(=O)CCC1C2=CC3=NC(=CC4NC(C=C5N=C(C=C(N2)C=1C)[C@]1(C)[C@@H](C(=CC=C15)C(=O)OC)C(=O)OC)=C(C)C=4C=C)C(C)=C3CCC(O)=O

4-dioxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3

and serves as an excellent chemical probe for investigating DOT1L and further development of DOT1L inhibitors for cancer therapy

is a potent autophagy inhibitor and TLR9 inhibitor

CUDC-101 - HDAC/EGFR/HER2 Inhibitor. CAS# 1012054-59-9 60129 Smiles: COC(=O)CCC1C2=CC3=NC(=CC4NC(C=C5N=C(C=C(N2)C=1C)[C@]1(C)[C@@H](C(=CC=C15)C(=O)OC)C(=O)OC)=C(C)C=4C=C)C(C)=C3CCC(O)=OCUDC 101, CAS No. 1012054 59 9, is a potent multi target inhibitor targeting HDAC, EGFR and HER2 with IC50 of 4. 4 nM, 2. 4 nM, and 15. 7 nM, respectively. It is specific for class I and class II HDACs, not for class III Sir type HDACs, and has > 50 fold selectivity against other protein kinases. CUDC 101 displays broad antiproliferative activity in many human cancer cell types with IC50 of 0. 04 0. 80 M, exhibiting a higher potency than erlotinib,